Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

University Lab Crammed Too Late To Avoid US FDA Warning Letter

Executive Summary

After a student analyst was caught fabricating Smithfield heparin data, Miami University chemistry department established a quality system and more than 20 quality procedures in time for an FDA inspection, but to no avail. The warning letter that followed was predicated on failures that had already occurred.

You may also be interested in...



Heparin Adulteration Triggered Pharmaceutical Identity Crisis

Pharmaceutical identity crisis arises after ingredients are mimicked by cheap, deadly substitutes. Chemical sleuths tell how they found the melamine cyanurate, oversulfated chondroitin sulfate and diethylene glycol that were hidden in pet food, heparin and cold remedies. Efforts to better identify drug ingredients takes on new urgency with melamine spreading to infant formula and rumors of possible attempts to devise a new heparin adulterant. As instrumental compendial tests are added to monographs, industry, legislators, regulators and compendial organizations grapple with broader implications of this new type of adulteration. U.S. Pharmacopeia leadership talks about establishing a massive standardized spectral library that could be accessed using remote analyzers to instantly identify ingredients, impurities and adulterants.

Heparin Case Highlights Vulnerabilities of Global Supply Chain

WHO'S NEXT? Baxter's heparin woes, related to a supply chain that stretches all the way to pig farms in China, raise questions about the ability of drug manufacturers to ensure the quality of drugs produced by globally sprawling enterprises. While the search for a root cause continues, some lessons already are clear: you can't always count on FDA or host nation regulators to police suppliers; you can't always be sure of your own ability to routinely detect deadly contaminants; and if something goes wrong, it could be front page news everywhere

CMC And GMP Updates In Brief: Continuous Manufacturing, Accelerated CMC Reviews

ICH  general assembly adopts guidelines on continuous manufacturing and risk management; US FDA opens pilot project to expedite CMC reviews for products with accelerated review timelines; other recent topics include quality maturity inspections and compounding standards.

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS146259

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel